Literature DB >> 10887144

Protein 4.1R binding to eIF3-p44 suggests an interaction between the cytoskeletal network and the translation apparatus.

C L Hou1, C j Tang, S R Roffler, T K Tang.   

Abstract

Erythroid protein 4.1 (4.1R) is an 80-kd cytoskeletal protein that stabilizes the membrane-skeletal network structure underlying the lipid bilayer. Using the carboxyl terminal domain (22/24 kd) of 4.1R as bait in a yeast 2-hybrid screen, we isolated cDNA clones encoding a polypeptide of eIF3-p44, which represents a subunit of a eukaryotic translation initiation factor 3 (eIF3) complex. The eIF3 complex consists of at least 10 subunits that play an essential role in the pathway of protein translation initiation. Northern blot analysis revealed that eIF3-p44 (approximately 1.35 kb) is constitutively expressed in many tissues. The essential sequence for this interaction was mapped to the carboxyl-terminus of 4.1R (residues 525-622) and a region (residues 54-321) of eIF3-p44. The direct association between 4.1R and eIF3-p44 was further confirmed by in vitro binding assays and coimmunoprecipitation studies. To characterize the functions of eIF3-p44, we depleted eIF3-p44 from rabbit reticulocyte lysates either by anti-eIF3-p44 antibody or by GST/4.1R-80 fusion protein. Our results show that the eIF3-p44 depleted cell-free translation system was unable to synthesize proteins efficiently. The direct association between 4.1R and elF3-p44 suggests that 4.1R may act as an anchor protein that links the cytoskeleton network to the translation apparatus. (Blood. 2000;96:747-753)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10887144

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Sum1, a component of the fission yeast eIF3 translation initiation complex, is rapidly relocalized during environmental stress and interacts with components of the 26S proteasome.

Authors:  Isabelle Dunand-Sauthier; Carol Walker; Caroline Wilkinson; Colin Gordon; Richard Crane; Chris Norbury; Tim Humphrey
Journal:  Mol Biol Cell       Date:  2002-05       Impact factor: 4.138

2.  Inhibition of protein 4.1 R and NuMA interaction by mutagenization of their binding-sites abrogates nuclear localization of 4.1 R.

Authors:  Subhendra N Mattagajasingh; Shu-Ching Huang; Edward J Benz
Journal:  Clin Transl Sci       Date:  2009-04       Impact factor: 4.689

3.  Protein 4.1 R-135 interacts with a novel centrosomal protein (CPAP) which is associated with the gamma-tubulin complex.

Authors:  L Y Hung; C J Tang; T K Tang
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

4.  Pelota interacts with HAX1, EIF3G and SRPX and the resulting protein complexes are associated with the actin cytoskeleton.

Authors:  Ozanna Burnicka-Turek; Aleksandra Kata; Byambajav Buyandelger; Linda Ebermann; Nadine Kramann; Peter Burfeind; Sigrid Hoyer-Fender; Wolfgang Engel; Ibrahim M Adham
Journal:  BMC Cell Biol       Date:  2010-04-20       Impact factor: 4.241

5.  Poly(A)-binding protein-interacting protein 1 binds to eukaryotic translation initiation factor 3 to stimulate translation.

Authors:  Yvan Martineau; Mélanie C Derry; Xiaoshan Wang; Akiko Yanagiya; Juan José Berlanga; Ann-Bin Shyu; Hiroaki Imataka; Kalle Gehring; Nahum Sonenberg
Journal:  Mol Cell Biol       Date:  2008-08-25       Impact factor: 4.272

6.  An internal ribosome entry site element directs the synthesis of the 80 kDa isoforms of protein 4.1R.

Authors:  Eva Lospitao; Carmen M Pérez-Ferreiro; Altea Gosálbez; Miguel A Alonso; Isabel Correas
Journal:  BMC Biol       Date:  2008-12-04       Impact factor: 7.431

7.  Identification of a distinct class of cytoskeleton-associated mRNAs using microarray technology.

Authors:  Amy Brock; Sui Huang; Donald E Ingber
Journal:  BMC Cell Biol       Date:  2003-07-08       Impact factor: 4.241

8.  Nuclear distribution of eIF3g and its interacting nuclear proteins in breast cancer cells.

Authors:  Qiaoli Zheng; Hao Liu; Jingjia Ye; Hui Zhang; Zhenyu Jia; Jiang Cao
Journal:  Mol Med Rep       Date:  2016-02-23       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.